Cohance Lifesciences receives EIR from USFDA for API Unit-IV in Telangana

26 May 2025 Evaluate

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection conducted at its API Unit-IV, located at Plot No. A-21, Road No. 10, IDA Nacharam, Uppal Mandal, Medchal-Malkajgiri, Telangana, India, from March 3, 2025 to March 7, 2025. 

The inspection was classified as Voluntary Action Indicated (VAI) and indicates the formal closure of the inspection process by the USFDA. The company remain committed to maintaining the highest standards of quality and regulatory compliance in all its operations.

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. 


Cohance Lifesciences Share Price

293.00 -2.80 (-0.95%)
11-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.90
Dr. Reddys Lab 1325.50
Cipla 1329.90
Zydus Lifesciences 922.00
Lupin 2345.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×